目次

Table of Content

1. Research Methodology

2. CD47 As Novel Cancer Immunotherapy Target

3. CD47 Clinical Application and Development Outlook By Indication
3.1 Solid Cancers
3.1.1 Breast Cancer
3.1.2 Gastrointestinal Cancer
3.1.3 Lung Cancer
3.1.4 Urogenital and Gynecologic Cancers
3.1.5 Head and Neck Cancer
3.2 Hematological Malignancies
3.2.1 Lymphoma
3.2.2 Leukemia
3.2.3 Multiple Myeloma
3.2.4 Myelodysplastic syndrome
3.3 Microbial Infections
3.4 Cardiovascular Diseases

4. Global CD47 Inhibitors Drug Clinical Pipeline Overview
4.1 By Country
4.2 By Company
4.3 By Indication
4.4 By Phase
4.5 By Priority Status

5. CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication and Phase
5.1 Research
5.2 Preclinical
5.3 Phase I
5.4 Phase I/II
5.5 Phase II
5.6 Phase II/III
5.7 Phase III

6. Global CD47 Inhibitor Drug Market Opportunity Outlook
6.1 Current Market Overview
6.2 Future Outlook and Opportunities

7. CD47 Inhibitor Drugs Clinical Developments and Trends By Country
7.1 China
7.2 US
7.3 South Korea
7.4 Australia
7.5 Canada

8. Global CD47 Inhibitors Market Dynamics
8.1 Favorable Parameters
8.2 Market Restraints

9. Competitive Landscape
9.1 Adagene
9.2 Akeso
9.3 ALX Oncology
9.4 Chia Tai Tianqing Pharmaceutical Group
9.5 EpicentRx
9.6 ImmuneOncia Therapeutics
9.7 ImmuneOnco Biopharma
9.8 Light Chain Bioscience
9.9 Phanes Therapeutics
9.10 Virtuoso Therapeutics

List of Figures
Figure 2-1: CD47-SIRPandalpha; Axis and Its Role In Immune Evasion
Figure 2-2: CD47 Blockade - Mechanisms Of Action
Figure 2-3: CD47 Targeted Therapies - Development Timeline
Figure 3-1: PRE-I-SPY-PI Phase I Study (NCT05868226) - Initiation and Completion Year
Figure 3-2: I-SPY 2 Phase I Study (NCT01042379) - Initiation and Completion Year
Figure 3-3: ZWI-ZW25-204 1/2 Phase I Study (NCT05027139) - Initiation and Completion Year
Figure 3-4: LCB-1801-001 Phase I Study (NCT05403554) - Initiation and Completion Year
Figure 3-5: AK112-206 Phase II Study (NCT05382442) - Initiation and Completion Year
Figure 3-6: AT148006 Phase II/III Study (NCT05002127) - Initiation and Completion Year
Figure 3-7: TWINPEAK Phase I/II Study (NCT05482893) - Initiation and Completion Year
Figure 3-8: AK104-219 Phase II Study (NCT05960955) - Initiation and Completion Year
Figure 3-9: AK117-202 Phase I/II Study (NCT05214482) - Initiation and Completion Year
Figure 3-10: SKYBRIDGE Phase I/II Study (NCT05652686) - Initiation and Completion Year
Figure 3-11: HCC 21-193 Phase I/II Study (NCT05652686) - Initiation and Completion Year
Figure 3-12: HCB101-101 Phase I Study (NCT05892718) - Initiation and Completion Year
Figure 3-13: NCI-2021-08492 Phase I/II Study (NCT05025800) - Initiation and Completion Year
Figure 3-14: NCI-2022-06277 Phase II Study (NCT05507541) - Initiation and Completion Year
Figure 3-15: AK117-104 Phase I/II Study (NCT04980885) - Initiation and Completion Year
Figure 3-16: AK117-206 Phase I/II Study (NCT06387420) - Initiation and Completion Year
Figure 3-17: BHARAT-1 Phase I Study (NCT05607199) - Initiation and Completion Year
Figure 3-18: MagnetisMM-20 Phase I Study (NCT05675449) - Initiation and Completion Year
Figure 3-19: 21-122 Phase I Study (NCT05139225) - Initiation and Completion Year
Figure 3-20: U1111-1244-2598 Phase I/II Study (NCT04643002) - Initiation and Completion Year
Figure 3-21: AK117-103 Phase I/II Study (NCT04900350) - Initiation and Completion Year
Figure 3-22: AK117-205 Phase II Study (NCT06196203) - Initiation and Completion Year
Figure 4-1: Global - Number of CD47 Inhibitor Drugs Clinical Trial By Country, 2025 - 2026
Figure 4-2: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Company, 2025 - 2026
Figure 4-3: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Indication, 2025 - 2026
Figure 4-4: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Phase, 2025 - 2026
Figure 4-5: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Priority Status, 2025 - 2026
Figure 6-1: CD47 Targeted Therapy - Future Opportunities
Figure 8-1: Global CD47 Inhibitors Market - Drivers and Opportunities
Figure 8-2: Global CD47 Inhibitors Market - Challenges and Restraints